When a stock gets red hot, its share price can sometimes soar to unsustainable levels as euphoria ends up taking over. One of the hottest stocks to own this year has undoubtedly been Summit ...

Summit Therapeutics (NASDAQ:SMMT) is one of the 17 biotechnology stocks with more than 50% upside. As of the close of play on February 12, consensus sentiment around Summit Therapeutics (NASDAQ:SMMT) ...

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating for ...

A very bullish analyst move was the news generally responsible for Summit Therapeutics' (NASDAQ: SMMT) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before market ...

Summit Therapeutics reached a milestone in its Phase III trial for ivonescimab, aiming to treat second-line EGFR mutated advanced NSCLC. The FDA has fast tracked the HARMONi trial. Positive Phase III ...

Summit Therapeutics (NASDAQ:SMMT) shares soar 51% after its investigational bispecific antibody, ivonescimab, reduced the risk of disease progression or death by 49% compared to Merck’s (NYSE:MRK) ...

Ivonescimab is a promising cancer drug that has sent its shares soaring in the past year. The drug isn't approved yet, but it's involved in dozens of trials and has shown promise. The stock's high ...

Summit Therapeutics Inc. (NASDAQ:SMMT) on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second ...

Summit Therapeutics Inc (NASDAQ:SMMT) stock is trading lower on Friday. On Thursday, Summit Therapeutics’ partner Akeso Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-1 ...

Summit investors are bullish on ivonescimab, which recently outperformed Keytruda in a clinical trial. Ivonescimab isn't approved yet, but investors are buying the stock as if the drug will be the ...